U.S. Capital Wealth Advisors’s Moderna MRNA Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,061	Closed	-$2.38M	–	684
2023 Q3	$2.38M	Buy	23,061 +7,893	+52%	+$880K	0.11%	173
2023 Q2	$1.84M	Buy	15,168 +10,155	+203%	+$1.35M	0.09%	225
2023 Q1	$770K	Buy	5,013 +2,199	+78%	+$363K	0.04%	349
2022 Q4	$505K	Sell	2,814 -550	-16%	-$89.9K	0.02%	449
2022 Q3	$398K	Buy	3,364 +250	+8%	+$37.9K	0.02%	481
2022 Q2	$445K	Sell	3,114 -164	-5%	-$23.4K	0.02%	491
2022 Q1	$565K	Buy	+3,278	New	+$552K	0.02%	488

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

U.S. Capital Wealth Advisors's MRNA Position: Q4 2023 in Review

U.S. Capital Wealth Advisors sold out of Moderna (MRNA) in Q4 2023, closing a stake of 23,061 shares — an estimated $2.38M sold.

U.S. Capital Wealth Advisors first reported a position in MRNA in Q1 2022 and held it in 7 quarters. The position peaked at $2.38M in Q3 2023. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

U.S. Capital Wealth Advisors reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 23,061 Moderna shares in Q4 2023, an estimated $2.38M.
U.S. Capital Wealth Advisors first reported a position in Moderna in Q1 2022 and held it in 7 quarters.
U.S. Capital Wealth Advisors's Moderna position peaked at $2.38M in Q3 2023.
884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q4 2023, filed 6 Feb 2024.